NZ207753A - Pharmaceutical composition containing sulpiride - Google Patents
Pharmaceutical composition containing sulpirideInfo
- Publication number
- NZ207753A NZ207753A NZ207753A NZ20775384A NZ207753A NZ 207753 A NZ207753 A NZ 207753A NZ 207753 A NZ207753 A NZ 207753A NZ 20775384 A NZ20775384 A NZ 20775384A NZ 207753 A NZ207753 A NZ 207753A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sulpiride
- methacrylates
- weight
- compositions
- microgranules
- Prior art date
Links
- 229960004940 sulpiride Drugs 0.000 title claims description 32
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 title claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 17
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 9
- 230000007935 neutral effect Effects 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000000454 talc Substances 0.000 claims description 6
- 229910052623 talc Inorganic materials 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 235000013681 dietary sucrose Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 229920001800 Shellac Polymers 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004208 shellac Substances 0.000 claims description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 3
- 229940113147 shellac Drugs 0.000 claims description 3
- 235000013874 shellac Nutrition 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 12
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000007891 compressed tablet Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 238000000576 coating method Methods 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- SSONCJTVDRSLNK-UHFFFAOYSA-N 2-methylprop-2-enoic acid;hydrochloride Chemical compound Cl.CC(=C)C(O)=O SSONCJTVDRSLNK-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- -1 methyl 2-methoxy 5-sulphamoyl benzamide Chemical compound 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical group CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8320635A FR2556964A1 (fr) | 1983-12-23 | 1983-12-23 | Nouvelles formes galeniques du sulpiride utilisables par voie orale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ207753A true NZ207753A (en) | 1987-08-31 |
Family
ID=9295477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ207753A NZ207753A (en) | 1983-12-23 | 1984-04-05 | Pharmaceutical composition containing sulpiride |
Country Status (38)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8414220D0 (en) * | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
| EP0212746B1 (en) * | 1985-08-16 | 1991-04-10 | The Procter & Gamble Company | Drug particles having constant release |
| US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
| JPH0791184B2 (ja) * | 1988-03-31 | 1995-10-04 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
| GB8903328D0 (en) * | 1989-02-14 | 1989-04-05 | Ethical Pharma Ltd | Nifedipine-containing pharmaceutical compositions and process for the preparation thereof |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| FR2762213B1 (fr) * | 1997-04-18 | 1999-05-14 | Synthelabo | Composition pharmaceutique a retention gastrique |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3342826A (en) * | 1964-01-13 | 1967-09-19 | Ile De France | Heterocyclic aminoalkyl benzamides |
| FR2313915A1 (fr) * | 1976-01-26 | 1977-01-07 | Corneille Gilbert | Nouvelle forme galenique d'administration de la vincamine et de ses derives, son procede de preparation et medicaments comprenant cette nouvelle forme |
| US4285665A (en) * | 1978-05-08 | 1981-08-25 | Johnson, Matthey & Co., Limited | Engines |
| FR2453639A1 (fr) * | 1979-04-09 | 1980-11-07 | Sanofi Sa | Composition medicamenteuse a liberation programmee immediate-retard a base de naftidrofuryl |
| FR2453642A1 (fr) * | 1979-04-12 | 1980-11-07 | Sanofi Sa | Compositions therapeutiques a usage oral et a liberation programmee du methanesulfonate de dihydroergotoxine |
| FR2454804B1 (fr) * | 1979-04-26 | 1986-11-21 | Sanofi Sa | Medicament a base de dihydroergotoxine et son procede de preparation |
| FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| SE8003805L (sv) * | 1980-05-21 | 1981-11-22 | Haessle Ab | En farmaceutisk beredning med forbettrade utlosningsegenskap |
| JPS5753326A (en) * | 1980-09-17 | 1982-03-30 | Dainippon Printing Co Ltd | Manufacture of biaxially stretching blow molded vessel of saturated polyester |
| FR2492661A1 (fr) * | 1980-10-28 | 1982-04-30 | Laruelle Claude | Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme |
| FR2494112B1 (enrdf_load_stackoverflow) * | 1980-11-19 | 1986-01-10 | Laruelle Claude | |
| FR2534139B1 (fr) * | 1982-10-07 | 1986-08-29 | Laruelle Claude | Nouvelle forme galenique du sulpiride, son procede de preparation et medicament comprenant cette nouvelle forme |
-
1983
- 1983-12-23 FR FR8320635A patent/FR2556964A1/fr not_active Withdrawn
-
1984
- 1984-03-30 IS IS2900A patent/IS1364B6/is unknown
- 1984-04-02 IE IE817/84A patent/IE57164B1/en not_active IP Right Cessation
- 1984-04-04 EP EP84400661A patent/EP0147244A1/fr not_active Withdrawn
- 1984-04-04 MA MA20309A patent/MA20088A1/fr unknown
- 1984-04-05 ZA ZA842573A patent/ZA842573B/xx unknown
- 1984-04-05 BE BE1/10992A patent/BE899331A/fr not_active IP Right Cessation
- 1984-04-05 CZ CS842629A patent/CZ262984A3/cs unknown
- 1984-04-05 DE DE19843412868 patent/DE3412868A1/de not_active Withdrawn
- 1984-04-05 NZ NZ207753A patent/NZ207753A/en unknown
- 1984-04-06 LU LU85290A patent/LU85290A1/fr unknown
- 1984-04-06 IT IT48001/84A patent/IT1177655B/it active
- 1984-04-06 FI FI841376A patent/FI82603C/fi not_active IP Right Cessation
- 1984-04-06 PH PH30510A patent/PH21938A/en unknown
- 1984-04-06 HU HU841362A patent/HU190924B/hu not_active IP Right Cessation
- 1984-04-06 NO NO841367A patent/NO169575C/no unknown
- 1984-04-06 AR AR296218A patent/AR231398A1/es active
- 1984-04-06 GR GR74337A patent/GR79584B/el unknown
- 1984-04-06 YU YU640/84A patent/YU44762B/xx unknown
- 1984-04-06 JP JP59069883A patent/JPS60139616A/ja active Granted
- 1984-04-06 IN IN242/MAS/84A patent/IN160415B/en unknown
- 1984-04-06 BG BG064985A patent/BG49707A3/xx unknown
- 1984-04-06 CH CH1755/84A patent/CH659386A5/fr not_active IP Right Cessation
- 1984-04-06 SU SU843728542A patent/SU1478993A3/ru active
- 1984-04-06 OA OA58273A patent/OA07700A/xx unknown
- 1984-04-06 DK DK180784A patent/DK165729C/da not_active IP Right Cessation
- 1984-04-06 PT PT78382A patent/PT78382B/pt not_active IP Right Cessation
- 1984-04-06 GB GB08408978A patent/GB2151920B/en not_active Expired
- 1984-04-06 PL PL1984247098A patent/PL144356B1/pl unknown
- 1984-04-06 DD DD84261741A patent/DD220782A5/de not_active IP Right Cessation
- 1984-04-07 RO RO84114201A patent/RO89437A/ro unknown
- 1984-04-07 KR KR1019840001840A patent/KR910004570B1/ko not_active Expired
- 1984-04-08 IL IL71470A patent/IL71470A/xx unknown
- 1984-04-10 ZW ZW60/84A patent/ZW6084A1/xx unknown
- 1984-04-16 MX MX84101994U patent/MX7715E/es unknown
- 1984-04-24 ZM ZM20/84A patent/ZM2084A1/xx unknown
- 1984-05-03 ES ES532125A patent/ES8502332A1/es not_active Expired
- 1984-05-31 AU AU28904/84A patent/AU569516B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4578264A (en) | Retard form of pharmaceuticals with insoluble porous diffusion coatings | |
| FI83037C (fi) | Foerfarande foer framstaellning av en naproxen och natrium naproxentablett med styrd utloesning. | |
| US4367217A (en) | Dipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereof | |
| CA2406373C (en) | Controlled release paracetamol composition | |
| US4981695A (en) | Composition comprising L-dopa | |
| NZ200519A (en) | Sustained release pellet containing indoramin | |
| WO2000013687A2 (en) | Sustained release ranolazine formulations | |
| US7135465B2 (en) | Sustained release beadlets containing stavudine | |
| US11717501B2 (en) | Magnesium threonate compositions and uses thereof | |
| US4690927A (en) | Pharmaceutical compositions with analgesic properties and the preparation and use thereof | |
| JPH01168617A (ja) | ジルチアゼムの遅放出性無酸医薬製剤及びその製法 | |
| EP0418597A2 (en) | Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form | |
| NZ207753A (en) | Pharmaceutical composition containing sulpiride | |
| CA2309542A1 (en) | Novel oral dosage form for carvedilol | |
| SI9620036B (sl) | Derivat aminotetralina za terapijo kardiovaskularnih bolezni | |
| US5077294A (en) | Products containing verapamil or gallopamil and prazosin | |
| EP0145558B1 (fr) | Nouvelles formes galéniques du sulpiride utilisables par voie orale | |
| EP1233758A2 (de) | Natriumvalproat-granulat mit verringerter hygroskopizität | |
| WO2007143290A2 (en) | Delayed-release compositions of extended release forms of venlafaxine | |
| JPS60228410A (ja) | 持続性製剤 | |
| US20040086565A1 (en) | Chrono delivery formulations and method of treating atrial fibrillation | |
| GB2141930A (en) | Novel pharmaceutical preparations with anti-tumour effect | |
| MXPA00004573A (en) | Novel oral dosage form for carvedilol | |
| HK1075415A (en) | Sustained release ranolazine formulations | |
| AU2002305737A1 (en) | Taste-masking of highly water-soluble drugs |